MiNK Therapeutics to Participate at Upcoming B. Riley Securities Virtual Oncology Conference

Rhea-AI Summary

MiNK Therapeutics announced that Dr. Jennifer Buell, President and CEO, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on January 27, 2022, at 12:00 PM ET. The event will discuss the company's advancements in iNKT cell therapies aimed at treating cancer and immune-mediated diseases. Investors can access the live presentation and a replay through MiNK's website after the event.

MiNK is focused on developing scalable iNKT cell therapies, enhancing treatment options in oncology.

NEW YORK, Jan. 12, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that Dr. Jennifer Buell, President and CEO of MiNK, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on January 27^th, 2022, at 12:00 pm ET.

Access to the live presentation is available at https://www.webcaster4.com/Webcast/Page/2828/44096

A replay will be available after the call on the Events and Presentations page of the MiNK website at https://investor.minktherapeutics.com/events-and-presentations

About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, please visit https://minktherapeutics.com/.

Contact
MiNK Therapeutics 
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com 

 

FAQ

When is Dr. Jennifer Buell's presentation at the B. Riley Securities Virtual Oncology Investor Conference?

Dr. Jennifer Buell's presentation is scheduled for January 27, 2022, at 12:00 PM ET.

What is the focus of MiNK Therapeutics?

MiNK Therapeutics focuses on the development of allogeneic iNKT cell therapies for cancer and immune-mediated diseases.

Where can I access the replay of MiNK Therapeutics' conference presentation?

The replay will be available on the Events and Presentations page of the MiNK website after the call.

What time is the B. Riley Securities Virtual Oncology Investor Conference?

The conference will take place at 12:00 PM ET on January 27, 2022.

What type of therapies is MiNK Therapeutics developing?

MiNK Therapeutics is developing allogeneic, off-the-shelf iNKT cell therapies.